



P
R
O
G
R
A
M

2nd International Conference on

INNOVATIONS IN PHARMA R&D



November 2-4, 2026



Holiday Inn Boston Hotel

30 Washington St, Somerville, MA 02143

Organized by



gayatri@coinsymposia.com



www.pharm-science.com



Life Time Achievement Award @ Innopharm-2026



Dr. Donald E. Ingber

Wyss Institute at Harvard University, Boston, MA



“

InnoPharm-2026 is proud to announce that its 2026 Lifetime Achievement Award will be presented to Professor Donald E. Ingber, Founding Director and Core Faculty of the Wyss Institute at Harvard University, in recognition of his pioneering contributions to biologically inspired engineering, organ-on-chip technology, mechanobiology, and translational medicine. His visionary research has transformed biomedical innovation and significantly advanced drug discovery, disease modeling, and precision healthcare.

”



Dr. Daria Mochly-Rosen

Stanford University, Stanford, CA



“

InnoPharm-2026 is proud to announce that its 2026 Lifetime Achievement Award will be presented to Professor Daria Mochly-Rosen, Professor at Stanford University, in recognition of her pioneering research in protein kinase signaling and its translation into novel therapeutic strategies for cardiovascular, neurological, and metabolic diseases. Her groundbreaking discoveries have had a profound impact on pharmaceutical research and translational medicine, inspiring innovative approaches to improving human health.

”

Join Zoom Meeting

<https://us06web.zoom.us/j/83605970145?pwd=i36RoOglaiwz84El7NPWw5tEpQ2D8S.1>

Meeting ID: 83605970145


Passcode: CA@!ljfbs5

08:20-08:40 Registrations and Badge Pickup

08:40-09:00 Opening Remarks

KEYNOTE PRESENTATIONS

Moderator: B. Rita Alevriadou, University at Buffalo, Buffalo, NY



Daria Mochly Rosen

Stanford University, Stanford, CA

The SPARK Model of Translational Research in Academia; a 20 Years Report

Dr. Daria Mochly-Rosen is a professor at Stanford University and a leader in translational medicine. Her research focuses on cell signaling and therapeutic development, and she founded Stanford SPARK to help advance academic discoveries toward clinical applications.

09:00-09:30



Martin Schwartz

Yale School of Medicine, New Haven, CT

A Novel Target for Combating Vascular Inflammatory Disease

Dr. Martin A. Schwartz is a professor at Yale School of Medicine specializing in vascular biology and mechanotransduction. His research explores how cells respond to mechanical forces and how cellular signaling contributes to vascular inflammation and cardiovascular disease.

09:30-10:00



Debbie C. Crans

Colorado State University, Fort Collins, CO

Beyond the Active Species: Transformation Networks in Vanadium Pharmacology

Dr. Debbie C. Crans is a Professor of Chemistry and Cell and Molecular Biology at Colorado State University. Her research focuses on bioinorganic and bioorganic chemistry, particularly vanadium compounds and their applications in medicine. Her work explores the mechanisms of metal-based drugs and their potential applications in treating diseases such as cancer, diabetes, and tuberculosis.

10:00-10:30



Coffee & Networking (10:30 - 10:50)



A. Thomas Look

Dana-Farber Cancer Institute

Harvard Medical School, Boston, MA

KAT6A/B Inhibitor Transcriptionally Upregulates GD2 to Sensitize Neuroblastoma Cells to Targeted Immunotherapy

Dr. A. Thomas Look is a professor at Harvard Medical School and a cancer researcher at Dana-Farber Cancer Institute. His research investigates the genetic and molecular mechanisms underlying leukemia, neuroblastoma, and other childhood cancers, with a focus on identifying potential therapeutic targets.

10:50-11:20

SPECIAL TALK

- 11:20–11:45** **Kenneth C. Waterman**, *FreeThink Technologies, Inc. Branford, CT*
The Accelerated Stability Assessment program (ASAP): Using Science to Rapidly Set Drug Product Shelf Life for Small Molecules and Biologics
- 11:45–12:10** **Zaher Nahle**, *Ivictory Group & Sr. Advisor, Bethesda, MD*
FDA Modernization Act 2.0 and 3.0



Group Photo & Lunch (12:10 - 13:20)

Session-I Drug Discovery & Optimization

Chair: Girish Nallur, *Vistara Bioscience, Guilford, CT*

- 13:20–13:40** **Barry Morgan**, *HitGen Inc., Franklin, MA*
25 years of DNA-encoded Library Technology: A Personal Perspective
- 13:40–14:00** **B. Rita Alevriadou**, *University at Buffalo, Buffalo, NY*
Mitochondrial Transfer Via Endothelial-Derived Extracellular Vesicles: A Potential Therapy for Vascular and Mitochondrial Diseases
- 14:00–14:20** **Eugenia Trushina**, *Mayo Clinic, Rochester, MN*
Advancing Mitochondrial Complex I Modulators for Neurodegenerative Diseases
- 14:20–14:40** **Jiayu Liao**, *University of California, Riverside, CA*
FDA-approved World's First Oral GLP1R Small-molecule Agonist
- 14:40–15:00** **Ronald Davis**, *University of Florida Health, Gainesville, FL*
Mitochondrial-targeted Therapeutics for ALS
- 15:00–15:20** **Philipp Mews**, *Boston University Chobanian & Avedisian School of Medicine, Boston, MA*
Epigenetic Therapeutics for Addiction: Targeting ACSS2 to Reduce Relapse Vulnerability
- 15:20–15:40** **Yuping Bao**, *The University of Alabama, Tuscaloosa, AL*
Transmembrane Proteins as Targets for Breast Cancer Drug Resistance
- 15:40–16:00** **Donald L Durden**, *Wake Forest University, Charlotte, NC*
In silico design of Multitarget Directed Ligands (MTDSs) for the Polypharmaceutical Treatment of Refractory Diseases
- 16:00–16:20** **Girish Nallur**, *Vistara Bioscience, Guilford, CT*
Targeted Peptide Interventions to Restore Proteostasis in Parkinson's Disease
-  **Coffee & Networking (16:20-16:40)**
- 16:40–17:00** **Ying-Xian Pan**, *New Jersey Medical School, Newark, NJ*
Establishing Oprm1 exon 7-associated Splice Variants as Therapeutic Targets for Improving Opioid Safety Without Compromising Analgesia
- 17:00–17:20** **Xiaofeng Tan**, *DeepCovalent, Inc., Acton, MA*
One-step De Novo Small-molecule Drug Discovery
- 17:20–17:35** **David Belnap**, *The University of Utah, Salt Lake City, UT*
Facilitating Commercial Drug Discovery at the University of Utah Electron Microscopy Core
-  **Cocktail Party & Networking (17:35-18:35)**

Join Zoom Meeting

<https://us06web.zoom.us/j/83605970145?pwd=i36RoOglaiwz84El7NPWw5tEpQ2D8S.l>

Meeting ID: 83605970145

Passcode: CA@!ljfbs5

KEYNOTE & PLENARY PRESENTATIONS

Chair: Thomas Caulfield, Digital Ether Computing, Miami, FL**Donald E. Ingber**

Harvard University, Boston, MA

Human Organ Chips for Disease Modeling, Drug Development, and Personalized Medicine

Dr. Donald E. Ingber is the Founding Director of the Wyss Institute at Harvard University. A pioneer in mechanobiology and biologically inspired engineering, his research focuses on Organ-on-Chip technology, tissue engineering, and innovative approaches to drug development and disease modeling.

**Rhoda Alani**

Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Epigenetic Inhibitors as Novel Therapeutics: Applications in Cancer and Beyond

Dr. Rhoda M. Alani is a physician-scientist specializing in cancer biology and molecular oncology. Her research focuses on the genetic and epigenetic mechanisms involved in tumor development and progression, supporting the discovery of potential new cancer therapies.

**Liwu Li**

Virginia Polytechnic Institute & State University, Blacksburg, VA

Rejuvenation of Innate Immunity for Treating Chronic Inflammatory Disease

Dr. Liwu Li is a professor at Virginia Tech specializing in innate immunity and inflammation biology. His research investigates immune signaling and the mechanisms underlying acute and chronic inflammatory diseases, with the goal of identifying new therapeutic strategies.

**Coffee & Networking (10:40-11:00)**

Session-II AI & ML in Pharma R&D

11:00-11:20 **Thomas Caulfield**, Digital Ether Computing, Miami, FL
TBA**11:20-11:40** **Naeyma Islam**, Mayo Clinic, Jacksonville, FL
Predicting Drug-likeness With or Without Structure: A Multi-modal ADMET Framework**11:40-12:00** **Diana Bohannon**, Absentia Labs, Somerville, MA
Bridging Translational Gaps in Drug-induced Liver Injury Using Predictive AI**12:00-12:15** **Alp Tartici**, Stanford, CA **(Flash Talk)**
Generative Denoising AI Models for Structure Guided Biologics Engineering

12:15–12:30 **Shourya Verma**, *Purdue University West, Lafayette, IN* **(Flash Talk)**
Towards Multi-modal Cellular Perturbation Modelling



Lunch (12:30-13:30)

Session-III Drug Delivery Systems & Biologics

Chair: **Peter F. Kador**, *UNMC & Therapeutic Vision, Inc., Omaha, NE*

13:30–13:50 **David K. Imagawa**, *UC Irvine School of Medicine, Irvine, CA*
Development of a Novel Drug Delivery System for Solid Organ Tumors

13:50–14:10 **Urszula Komarnicka**, *University of Wrocław, Poland*
Organometallic (Fe, Ru, Ir, and Os) Phosphine-based Inducers of Ferroptosis in Drug-resistant Cancer Cells and their Applications in Drug Delivery

14:10–14:30 **Ananth Kumar Kammala**, *The University of Texas Medical Branch at Galveston, Galveston, TX*
Exosome-based Biologics: A New Frontier in Drug Development and Precision Medicine

14:30–14:50 **Gihoon Lee**, *Johnson & Johnson Innovative Medicine, Spring House, PA*
Proteomics-based Discovery of Cellular Mechanisms Driving CHO Productivity

14:50–15:10 **Shanhu Hu**, *WuXi AppTec Co., Ltd., Boston, MA*
Integrated Solutions for Advancing Oligonucleotide Drug Discovery

15:10–15:30 **Tania (Tali) Konry**, *Bouvé College of Health Sciences, Northeastern University, Boston, MA*
Beyond Omics: Functional Immunology as a New Engine for Drug Discovery and Biomarker Development

15:30–15:50 **Zhimin Cao**, *SUNY Upstate Medical University, Syracuse, NY*
Triple-negative Breast Cancer-evidence of Successful Treatment Using Chinese Herb Extract in Animal Model

15:50–16:10 **Peter F. Kador**, *UNMC & Therapeutic Vision, Inc., Omaha, NE*
Orally Active Multifunctional Redox Modulators are Neuroprotective for Vision, Hearing and Cognition



Coffee & Networking (16:10-16:30)

16:30–16:50 **Yangmei Li**, *University of South Carolina, Columbia, SC*
Developing Cyclic Peptide MOR/DOR Dual Agonists as Safe and Potent Analgesics Without Abuse Liability

16:50–17:10 **Hu Yang**, *Marquette University, Milwaukee, WI*
Drug Delivery and Nanomedicine Strategies for Glaucoma

17:10–17:30 **Changning Wang**, *Massachusetts General Hospital Brigham and Women's Hospital, Boston, MA*
Molecular Imaging in Drug Discovery

17:30–17:50 **Thoa Tran**, *Indiana University School of Medicine, Indianapolis, IN*
Bridging the Gap in Aptamer-based Cancer Therapy: Engineering Tunable Photodynamic Therapy for Cancer Treatment

17:50–18:20 **Jan E. Schnitzer**, *PRISM, La Jolla, CA*
Challenges and solutions on delivering Precision Medicine today

Join Zoom Meeting

<https://us06web.zoom.us/j/83605970145?pwd=i36RoOglaiwz84El7NPWw5tEpQ2D8S.1>

Meeting ID: 83605970145

Passcode: CA@!ljfbs5

Chair: Diane Joseph-McCarthy, Boston University, Boston, MA

Session-IV Clinical Research & Precision Medicine

- 08:15–08:40** **Diane Joseph-McCarthy**, Boston University, Boston, MA
Machine Learning Enabled Drug Design
- 08:40–09:00** **Yoko Ambrosini**, Washington State University, Pullman, WA **(Special Talk)**
TBA
- 09:00–09:20** **Roger Giese**, Northeastern University, Boston, MA
The Missing Cancer Prevention Test: Next Generation DNA Adductomics
- 09:20–09:40** **Hoon-Ki Sung**, The Hospital for Sick Children, Canada
Rejuvenating Adipose Tissue: From Drug Repurposing to Dietary Interventions



VIRTUAL PLENARY

Joseph Wu

Stanford University, Stanford, CA

New Approach Methodologies (NAMs): Human-centric biology for drug discovery

Dr. Joseph C. Wu is a professor at Stanford University School of Medicine and Director of the Stanford Cardiovascular Institute. His research focuses on cardiovascular disease, stem cell biology, precision medicine, and drug discovery, including human-relevant models for evaluating potential therapies.

**Coffee & Networking (10:20-10:40)**

- 10:40–11:00** **Bradley M. Palmer**, University of Vermont, Burlington, VT
Cardiac Slice Preparation and Pressure-volume Work Loop Mimicry for Drug Discovery
- 11:00–11:20** **Shari Price**, National Institutes of Health, Frederick, MD
In Vitro Cardiac Safety Assessments using New Approach Methodologies (NAMs) in 2D and 3D Formats
- 11:20–11:40** **Amir Reza Aref**, Harvard Medical School, Boston, MA
Micro-physiological Systems Developing a Functional Precision Medicine for Immuno-oncology
- 11:40–12:00** **Alain Bicart-Sée**, Hôpital Joseph Ducuing, France
Kinetics of Molecular Patterns Captured by Mannose-binding Lectin in Septic Shock Correlate With Clinical Outcome: A Monocentric Prospective Observational Study
- 12:00–12:20** **Su Ryon Shin**, Harvard Medical School, Cambridge, MA
Nano-and Micro-engineered Biomaterials Modulating Stem Cells Behavior for Regenerative Medicine
- 12:20–12:40** **Katherine C. MacNamara**, Albany Medical College, Albany, NY
Targeting Resolution Programs to Improve Immunosuppression in Autoimmune Disease
- 12:40–13:00** **Jienyu Ding**, The National Institutes of Health Bethesda, MD
Bottom Up Reconstitution of Integrin Based Focal Adhesion Machinery
- 13:00–13:20** **Ameer H. El-Afandi**, Medical College of Wisconsin, Milwaukee, WI
Weighing In as a Team: Managing Obesity Through Interdisciplinary Group Visits

13:20-13:40 **Matthew Caporizzo**, *University of Vermont, Burlington, VT*
Providing a Clinical Grade of Diastolic Function in a Small Myocardial Slice

13:40 Lunch & Departures

VIRTUAL PRESENTATIONS


Join Zoom Meeting

<https://us06web.zoom.us/j/83605970145?pwd=i36RoOglaiwz84EI7NPWa5tEpQ2D8S.1>

Meeting ID: 83605970145

Passcode: CA@!!jfs5

14:20-14:30 Virtual Introductions



Ernst Wagner

Ludwig-Maximilians-Universität München, Germany

Chameleon Nanocarriers for RNA delivery

Dr. Ernst Wagner is a Professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität München, Germany. His research focuses on nucleic acid therapeutics, gene delivery, nanomedicine, polymer-based drug delivery systems, and the development of innovative technologies for RNA therapeutics and genome editing.

14:30-15:00

15:00-15:20 **Basil Golding**, *CBER | US FDA, Silver Spring, MD*
The Impact of Cognate Antigen on Antibody Distribution

15:20-15:40 **William R. Kem**, *University of Florida Health, Gainesville, FL*
The Alpha6Beta2 Nicotinic Receptor as a Preferred Target for Treating Tobacco Addiction

KEYNOTE PRESENTATIONS



Nathan D. Wong

University of California, Irvine, CA

Lipoprotein(a): A Powerful Driver of Cardiovascular Risk and Emerging Therapeutic Options

Dr. Nathan D. Wong is a Professor of Medicine and Epidemiology at the University of California, Irvine, and Director of its Heart Disease Prevention Program. His research focuses on cardiovascular epidemiology, preventive cardiology, coronary artery calcium, diabetes, and the prevention and management of cardiovascular disease.

15:40-16:10



Pal Pacher

National Institute of Health, Rockville, MD

Title to be Announced!

Dr. Pál Pacher is a Senior Investigator at the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. His research focuses on oxidative stress, inflammation, cardiovascular disease, and tissue injury, with an emphasis on identifying molecular mechanisms and potential therapeutic targets.

16:10-16:40



Nicolas G. Bazan

LSU Health New Orleans, New Orleans, LA

Title to be Announced!

Dr. Nicolas G. Bazan is Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans. His research focuses on neuroscience, retinal degeneration, and neuroprotection, particularly the molecular mechanisms involved in neuronal survival and brain and retinal diseases

17:10-17:30 **Michael E. Green**, *The City College of New York, New York, NY*
Water, Protons, and Gating the Kv1.2 and Shaker Potassium Ion Channels



Coffee & Networking (17:30-17:50)

17:50-18:10 **Shuiying Hu**, *The Ohio State University, Columbus, OH*
Title to be Announced!

18:10-18:30 **Rana Rais**, *Johns Hopkins Drug Discovery, Baltimore, MD*
A Tumor-targeted Prodrug Strategy for Glutamine Antagonism

18:30-18:50 **Gina D'Angelo**, *AstraZeneca Gaithersburg, MD*
From Discovery to Impact: Biomarkers Powering the Future of Precision Medicine

18:50-19:10 **Kumaraswamy Naidu Chitrala**, *University of Houston, Houston, TX*
Multi-omics Approaches to Discover Molecular Targets Associated with Health Disparities in Human Diseases

19:10-19:30 **Hira L. Nakhasi**, *U.S. Food and Drug Administration, Silver Spring, MD*
Development of Genetically Modified Live Attenuated Leishmania Vaccine- from Bench to Bed side

19:30-19:50 **Asmita Khanolkar**, *SMC Ltd, Boston, MA*
Developing Combination Products for the Evolving Therapeutic Drug-device Landscape

19:50-20:10 **Taeyoon Jung**, *Johns Hopkins Drug Discovery, Baltimore, MD*
Gut-restricted GCPII-steroid Conjugate for IBD

20:30 **Closing Remarks**

NETWORKING CONFERENCING INNOVATING

Attending a Conference isn't all about Learning and Networking

DISCOVERING

A right choice of conference destination is an important aspect of any international conference. Keeping this in consideration, **InnoPharm-2026 – The Second International Conference on Innovations in Pharma R&D** is scheduled in the vibrant and historic city of **Boston, Massachusetts, USA**.

BOSTON, MA

Boston, Massachusetts, is a vibrant and historic city that attracts visitors from around the world. Known for its prestigious universities, historic architecture, cultural attractions, and thriving pharmaceutical and biotechnology industries, Boston offers a unique blend of American history, academic excellence, and modern innovation. It is an ideal destination for international conferences, bringing together researchers, industry professionals, and scientific innovators.

Freedom Trail: One of Boston's most popular attractions, the Freedom Trail is a historic walking route connecting significant landmarks associated with the American Revolution. Visitors can explore historic churches, meeting houses, and monuments while discovering the city's important role in American history.

Harvard University: Located in nearby Cambridge, Harvard University is one of the world's most renowned academic institutions. Visitors can explore its historic Harvard Yard, admire the beautiful campus architecture, and experience the rich academic atmosphere that makes the Boston area a global center for education and research.

Museum of Fine Arts, Boston: A major cultural attraction, the Museum of Fine Arts features an extensive collection of artworks from different periods and cultures. Along with Boston Common and the Public Garden, it offers visitors opportunities to enjoy art, nature, and relaxation while experiencing the charm of this remarkable city.



We wish to see you at

INNOPHARM-2027

Organized By



CO-IN Symposia LLC

 <https://pharm-science.com>

 # 5900 Balcones Dr Suit 100, Austin, TX 78731

 +1-512-270-2990

 gayatri@coinsymposia.com